74,979 research outputs found
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
Full text linkOral capecitabine (Xeloda<sup>®</sup>) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not yet approved by the UK National Institute for Health and Clinical Excellence (NICE) in the adjuvant setting. Adjuvant capecitabine is at least as effective as 5-fluorouracil/leucovorin (5-FU/LV), with significant superiority in relapse-free survival and a trend towards improved disease-free and overall survival. We assessed the cost-effectiveness of adjuvant capecitabine from payer (UK National Health Service (NHS)) and societal perspectives. We used clinical trial data and published sources to estimate incremental direct and societal costs and gains in quality-adjusted life months (QALMs). Acquisition costs were higher for capecitabine than 5-FU/LV, but higher 5-FU/LV administration costs resulted in 57% lower chemotherapy costs for capecitabine. Capecitabine vs 5-FU/LV-associated adverse events required fewer medications and hospitalisations (cost savings £3653). Societal costs, including patient travel/time costs, were reduced by >75% with capecitabine vs 5-FU/LV (cost savings £1318), with lifetime gain in QALMs of 9 months. Medical resource utilisation is significantly decreased with capecitabine vs 5-FU/LV, with cost savings to the NHS and society. Capecitabine is also projected to increase life expectancy vs 5-FU/LV. Cost savings and better outcomes make capecitabine a preferred adjuvant therapy for Dukes' C colon cancer. This pharmacoeconomic analysis strongly supports replacing 5-FU/LV with capecitabine in the adjuvant treatment of colon cancer in the UK
Dr. Frank Fu, c. 1979
No full textA portrait photograph of Dr. Frank H. Fu (Fu Haojian). The photograph was used in news stories on Dr. Fu for his work and his appointment as Director of Springfield College's International Center.An author of 17 textbooks and more than 100 journal articles, Frank H. Fu, G’73, DPE’75, has worked across the world in China, Canada, and the United States. Throughout his career, he has received many distinguished honors, including the Medal of Honor in 2009 by the SAR Government of Hong Kong.
Fu has held positions at institutions such as the Chinese University of Hong Kong and Springfield College, where he served as director of the International Center starting in 1978. Five years later, Fu returned to Hong Kong, but has since remained actively involved with Springfield College, participating in talks on the campus and even hosting a gathering of nearly 60 alumni in Hong Kong.
Currently, Fu is the associate vice president of Hong Kong Baptist University, where he also works as the director of the Dr. Stephen Hui Research Centre of Physical Recreation and Wellness. In addition, Fu is president of the Society of Chinese Scholars on Exercise Physiology and Fitness, chairperson of Hong Kong Coach Education Committee, a research fellow of the Research Consortium of SHAPE America, and an international fellow of the National Academy of Kinesiology
Letter from C. H. Gensler, Havasupai Agency to Carl Hayden
No full textLetter from C. H. Gensler expressing concern on behalf of the Havasupai Tribe regarding the proposed park boundaries
Citations of the author H C Rajpoot
No full textThe list of the articles, research papers, theses, and book chapters globally citing the author H. C. Rajpoot</p
Letter from Carl Hayden to C. H. Gensler
No full textLetter from Carl Hayden to C. H. Gensler informing him of the proposed Grand Canyon National Park bill
Letter from C. H. Gensler, Havasupai Agency to Carl Hayden
No full textLetter from C. H. Gensler to Carl Hayden asking for a meeting in regards to the Havasupai pasture land in light of the national park bill
Isodesmic C–H Functionalization: Carboxyl-Assisted Remote meta- and ortho-C–H Iodination of Arenes via Shuttle Catalysis
No full textIsodesmic C–H
functionalization reactions are extremely rare. Herein
we report the first Pd(II)-catalyzed isodesmic C–H iodination of arenes using
2-nitrophenyl iodides as the mild iodinating reagents. Unusual C–I reductive
elimination occurred in preference to
competing C–C coupling in this reaction. Assisted by aliphatic carboxyl
directing groups, a range of hydrocinnamic acids and related arenes could be
selectively iodinated at either meta- or ortho-positions of the
phenyl ring. Remote diastereoselective C–H activation was also promising. This
method may open up a new way to iodinate challenging substrates
Silver-Mediated Direct sp(3) C-H Bond Functionalization
No full textDirect sp(3) C-H bond functionalization is an efficient, straightforward, and powerful method to construct new C-X (X = C, N, F, S) bonds from nonfunctionalized aliphatic motif of organic molecules, which has been used in late-stage modification of complex molecules. In this chapter, the recent developments of silver-mediated direct sp(3) C-H functionalizations are reviewed, categorized by C-C bond formation (C-H insertion), C-N bond formation (intramolecular and intermolecular amination/amidation), C-F bond formation, and C-S bond formation.SCI(E)[email protected]
The molecular structures, expression patterns, and promoter analysis of zebrafish troponin I genes
No full textMean ΔCq values (± standard deviation) of miRNAs from HBsAg particles per groups in Peg-IFN treated patients and inactive carriers [NR-BL (A); NR-Post-T-FU (B); REL BL (C); REL-Post-T-FU (D); SVR BL (E); SVR-Post-T-FU (F); IC (G); NR, REL, SVR BL and REL/NR Post-T-FU (H)].
No full text<p>On the right comparisons between groups F and E; G and E; F and H; G and H.</p><p>Mean ΔCq values (± standard deviation) of miRNAs from HBsAg particles per groups in Peg-IFN treated patients and inactive carriers [NR-BL (A); NR-Post-T-FU (B); REL BL (C); REL-Post-T-FU (D); SVR BL (E); SVR-Post-T-FU (F); IC (G); NR, REL, SVR BL and REL/NR Post-T-FU (H)].</p
- …
